Company Overview
NeuroPace, Inc. operates as a specialized medical device company within the United States, focusing on the development of the RNS system, a brain-responsive neuromodulation technology designed to deliver personalized, real-time treatment directly at the seizure source for patients suffering from drug-resistant focal epilepsy. This operational focus places the firm squarely within the Healthcare sector and the Medical Devices industry, where innovation in neurological treatment methods defines its market positioning and strategic relevance. The company's scale is characterized by a market capitalization of $455.51M and an annual revenue base of $99.99M, supported by a workforce of 209 employees. These financial dimensions indicate a mid-sized enterprise that has established a significant presence in a niche therapeutic area, yet the market cap relative to revenue suggests a valuation that heavily incorporates growth expectations and intellectual property value rather than current profitability.
Financial Health
The company reported revenue of $99.99M over the trailing twelve months, yet this top-line activity corresponds to a net income of -$21,465,000 and an EBITDA of -$16,100,000. The substantial gap between the nearly $100M in revenue and the negative net income reveals a cost structure where operating expenses, research and development costs, and other overheads significantly exceed the gross profit generated from sales. Free cash flow stands at -$3,959,875, indicating that the company is currently burning cash to fund its operations and growth initiatives, which limits immediate financial flexibility and reliance on external capital markets. Profitability analysis shows a gross margin of 77.2%, demonstrating strong pricing power or efficient production costs, while the operating margin of -6.6% and profit margin of -21.5% highlight the heavy expense burden required to maintain the device and conduct clinical activities. Liquidity and leverage metrics present a mixed picture: the firm holds $61.06M in cash against $70.84M in debt, resulting in a debt-to-equity ratio of 372.22, which signals a highly leveraged balance sheet. However, the current ratio of 5.28 suggests robust short-term liquidity, as the company possesses ample current assets to cover its immediate obligations despite the high debt load. Return metrics further illustrate the financial reality, with a return on equity of -158.7% and a return on assets of -10.2%, indicating that management effectiveness in generating shareholder value from the existing capital base is currently negative due to the ongoing losses.
Valuation Assessment
Valuation multiples reflect the company's loss-making status, with a trailing P/E ratio of N/A and a forward P/E of -38.29. The divergence between these metrics, specifically the negative forward P/E, implies that the market prices the stock based on expected future earnings recovery or asset value rather than current profitability, acknowledging a trajectory that remains unprofitable in the short term. The price-to-book ratio is 23.86, a figure that indicates a substantial market premium over the company's book value, suggesting that investors are pricing in significant future growth potential or unique technological advantages that are not captured on the balance sheet. Alternative valuation measures provide additional context, with a price-to-sales ratio of 4.56 and an EV/EBITDA of -28.90, which suggest that the stock is valued heavily on revenue generation rather than earnings power. Price action over the last year shows a 52-week high of $18.98 and a 52-week low of $7.56, meaning the current trading price sits within this range but reflects the volatility typical of high-growth, unprofitable biotech or medtech firms. The beta value is 1.86, which means the stock price is expected to be significantly more volatile than the broader market, amplifying gains and losses during periods of market fluctuation.
Growth & Income
The company demonstrates a revenue growth rate of 23.9% year-over-year, while earnings growth is listed as N/A due to the negative earnings base. The fact that revenue is growing while earnings remain negative implies that the company is investing heavily in scaling its operations or RNS system deployment, prioritizing market share expansion over immediate profit generation in the current phase. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash flow is being retained and reinvested into the business rather than distributed to shareholders. This reinvestment strategy is common for medical device companies in the development or commercialization phase, where capital is required to fund clinical trials, regulatory approvals, and manufacturing capacity. Overall, the growth and income profile is defined by rapid top-line expansion funded by retained earnings and cash reserves, with no current reliance on dividend income for shareholders.